ClinVar Miner

Submissions for variant NM_000251.2(MSH2):c.2006-1G>C (rs267607988)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
International Society for Gastrointestinal Hereditary Tumours (InSiGHT) RCV000076347 SCV000107373 likely pathogenic Lynch syndrome 2019-06-21 reviewed by expert panel curation Interrupts canonical donor splice site
Ambry Genetics RCV000491159 SCV000580477 pathogenic Hereditary cancer-predisposing syndrome 2020-02-27 criteria provided, single submitter clinical testing The c.2006-1G>C intronic pathogenic mutation results from a G to C substitution one nucleotide upstream from coding exon 13 of the MSH2 gene. This mutation has been identified in multiple patients satisfying Amsterdam Criteria I (ACI) with tumors lacking MSH2 expression on IHC (Stormorken AT, J. Clin. Oncol. 2005 Jul; 23(21):4705-12; Sjursen W, J. Med. Genet. 2010 Sep; 47(9):579-85). This mutation was identified in an additional patient diagnosed at age 37 with CRC lacking MSH2 expression on IHC (Nagasaka T, Cancer Res. 2010 Apr; 70(8):3098-108), in a patient with an MSI-H tumor and/or a family history meeting AC criteria (Mangold E, Int. J. Cancer 2005 Sep; 116(5):692-702) and in a patient with colon cancer at 43 with loss of expression of MSH2 and MSH6 on IHC who also had bilateral renal cancer at ages 50 and 58 (Moussa SA et al. Int J Colorectal Dis, 2011 Apr;26:455-67). Of note, this mutation is also called IVS12-1G>C in published literature. In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation.
Invitae RCV001379378 SCV001577172 likely pathogenic Hereditary nonpolyposis colorectal neoplasms 2020-02-09 criteria provided, single submitter clinical testing This sequence change affects an acceptor splice site in intron 12 of the MSH2 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). This variant has been observed in individual(s) with Lynch syndrome (PMID: 15849733, 16034045, 21311894). This variant is also known as IVS12-1G>C in the literature. ClinVar contains an entry for this variant (Variation ID: 90845). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in MSH2 are known to be pathogenic (PMID: 15849733, 24362816). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.